Control of *Klebsiella pneumoniae* Infection in Mice by Using Dissolving Microarray Patches Containing Gentamicin

Aoife M. Rodgers,a Maelíosa T. C. McCrudden,a Aaron J. Courtenay,a Mary-Carmel Kearney,a Katherine L. Edwards,b Rebecca J. Ingram,b Jose Bengoechea,b Ryan F. Donnellya

*a* School of Pharmacy, Medical Biology Centre, Queens University Belfast, Belfast, United Kingdom

*b* Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queens University Belfast, Belfast, United Kingdom

ABSTRACT Using a murine model of *Klebsiella pneumoniae* bacterial infection, we demonstrate that gentamicin dissolving microarray patches, applied to murine ears, could control *K. pneumoniae* infection. Mice treated with microarray patches had reduced bacterial burden in the nasal-associated lymphoid tissue and lungs compared with their untreated counterparts. This proof of concept study represents the first published data on the *in vivo* delivery of the antibiotic gentamicin via dissolving microarray patches, resulting in the control of bacterial infection.

KEYWORDS *Klebsiella pneumoniae*, gentamicin, microarray, transdermal delivery

Neonatal infections, including pneumonia and sepsis, remain a significant cause of mortality and morbidity, with an estimated 3 million neonatal deaths occurring every year worldwide (1). Neonates born in low- and middle-income countries are at greatest risk of mortality due to bacterial infections because of limited access to hospitals, facility-based care, or lifesaving antibiotics (2). In response to this, the World Health Organization (WHO) has provided guidelines for managing possible serious bacterial infections (PSBI) in young infants when referral to a hospital is not possible. Treatment includes intramuscular (i.m.) gentamicin (GEN) in combination with oral amoxicillin (AMX) (3).

GEN is a potent aminoglycoside antibiotic with bactericidal activity against Gram-negative bacteria and is widely utilized due to its efficacy and low cost (4). Similar to other aminoglycosides, GEN has a narrow therapeutic index and has the potential for ototoxicity and nephrotoxicity (5, 6). GEN is excreted in the kidneys primarily by glomerular filtration and has a short plasma elimination half-life in healthy individuals presenting with normal renal function (7). In neonates and young children, GEN half-life can vary according to weight, and thus, careful dose calculation based on infant weight is necessitated (8, 9). As a consequence of this, well-resourced settings have implemented therapeutic drug monitoring of GEN serum levels to reduce the incidence of toxicity (4). However, in outpatient resource-poor settings, this regimen has challenges and many neonates do not receive appropriate treatment (10). For those that do receive antibiotics, drug levels are unmonitored and first-line care is often provided by those lacking specialist pediatric training, often resulting in dose miscalculations and subsequent toxicity. As GEN must be delivered by i.m. injection, health care providers require access to safe injection supplies and sharps disposal, which is often unavailable in low-resource settings (11).

Based on the aforementioned challenges, it is evident that novel, simplified approaches are warranted to expand access to lifesaving antibiotics in this population group. Accordingly, we have developed dissolving microarray patches (MNs) (also known as microneedles) for transdermal delivery of GEN (7). MNs are minimally invasive devices that consist of an array of microscopic needles attached to a base support (12).
Upon insertion into the skin, the needles create microscopic holes, bypassing the stratum corneum barrier and subsequently delivering drug contained in the MNs into the viable skin (reviewed in reference 13). MNs are typically fabricated such that they are short enough to avoid stimulation of dermal nerves, and therefore, they provide a simplified, painless method of drug delivery that is well accepted by human subjects (14, 15). MNs offer the possibility for GEN delivery by less-experienced personnel and easier logistics for supplying to remote areas (16). As MNs dissolve upon insertion in the skin, they eliminate the requirement for sharps disposal and avoid transmission of blood-borne infections through needlestick injuries (17). Our previous work has demonstrated the successful transdermal delivery of therapeutically relevant concentrations of GEN using dissolving MNs in an in vivo model (7). However, the in vivo efficacy of antibiotics delivered transdermally via MN to control bacterial infection has yet to be demonstrated.

In this study, we aimed to test the therapeutic efficacy of antibiotics delivered via MNs. MNs containing GEN were prepared utilizing simplified manufacturing processes, as previously described (Fig. 1) (12). MNs were formulated from aqueous blends containing 3.4% sodium hyaluronate, with molecular weight (MW) 250 to 400 kDa, in combination with 1% polyvinylpyrrolidone (PVP; 58 kDa; Sigma-Aldrich, Dorset, UK) and containing 10% GEN sulfate (Tokyo Chemical Industry UK Ltd., Oxford, UK). Upon insertion of MNs into skin, the drug content in the needles is delivered concurrently with MN dissolution. Some drug may also diffuse into the skin layers from the baseplate, thus, allowing for sustained drug release (18). GEN exhibits a concentration-dependent bactericidal effect with peak and trough serum concentrations that are therapeutically effective and nontoxic. Sustained delivery of GEN, with peak serum levels above 10 to 12 μg/ml and trough serum levels above 2 μg/ml, may be toxic (7, 19). Accordingly, we fabricated MNs in two steps to localize the GEN content to needles and, thus, prevent toxicity associated with sustained GEN delivery. Thus, the baseplates contained no GEN and were formulated from 15% PVP (360 kDa). The resultant MNs had heights of approximately 500 μm and base widths of approximately 300 μm, as confirmed by microscopic analysis (Fig. 1).

We subsequently probed the capacity of GEN MNs to induce therapeutic effects in vivo. We tested the GEN MNs in a Klebsiella pneumoniae murine model of pneumonia. K. pneumoniae is one of the most important Gram-negative pathogens associated with a wide spectrum of infections, including pneumonia, intraabdominal infections and bloodstream infections (20, 21). GEN is a clinically relevant antibiotic treatment against K. pneumoniae, and therefore, this bacteria was selected as a model pathogen (22–24). Mice were infected with a live culture of K. pneumoniae (ATCC 43816) delivered intranasally (10^5 CFU per mouse in 30 μl of endotoxin-free phosphate-buffered saline [PBS]), and this results in dissemination 24 h postinfection. The inoculum was plated for confirmation of bacterial number/load. Following this, mice (n = 6 to 7/group) were treated as per the schematic in Fig. 2A. In short, 8 h post-K. pneumoniae infection, GEN MNs were applied to the dorsal surface of each murine ear and held in place using micropore tape for 24 h, after which they were removed and replaced with additional MNs. GEN delivered i.m. to the thigh muscle of the hind limb was included as control. At 48 h postinfection, mice were sacrificed and the organs were harvested for analysis of bacterial burden. Body weights were monitored over the course of infection; however, no significant differences between groups were observed 48 h postinfection (Fig. 2B). As demonstrated in Fig. 2C, mice which received GEN i.m. or GEN MNs exhibited a greater capability to control infection, as evidenced by reduced numbers of CFU in the nasal-associated lymphoid tissue (NALT) and lungs. A significant reduction in CFU was observed in the NALT (P = 0.0053) and lungs (P = 0.0006) of mice treated with MNs compared with their untreated counterparts, demonstrating the in vivo activity of GEN delivered via MN. Specifically, application of GEN MN resulted almost a two-log reduction in the number of CFUs in the NALT and a 3.4-log reduction in lung CFU. A one-way analysis of variance (ANOVA), followed by
correction for false discovery rate, was used for determination of statistical significance. A greater spread of results was evident in mice receiving GEN MNs than that of mice receiving GEN i.m., and this is likely attributable to the variability in the MNs manufactured under small-scale laboratory conditions. All experiments were performed in accordance with the UK Home Office and approved by the Queens University Belfast Ethical Review Committee.
In conclusion, the results presented herein collectively demonstrate that MNs containing GEN effectively control *K. pneumoniae* infection in mice. While further studies are warranted to demonstrate complete clearance, this is the first reported study utilizing MNs for the treatment of bacterial infection. MNs may be a potentially viable delivery platform for antibiotic delivery, offering the possibility to expand access to lifesaving antibiotic treatment in low-resource settings. As MNs dissolve upon insertion in the skin, they circumvent the generation of sharps waste and associated transmission of blood-borne pathogens. Our ongoing efforts entail the optimization of GEN MNs to increase bioavailability and develop a thorough understanding of the pharmacokinetics and pharmacodynamics of GEN delivered via this route compared with that delivered i.m. In the era of increasing antimicrobial resistance, novel approaches for empirical therapy are necessitated and MNs may offer an ideal solution. Importantly, as MNs bypass the gastrointestinal microbiota, they also offer an alternative delivery option for antibiotics that are currently delivered orally and could potentially prevent dysbiosis of the gut microbiota.

**ACKNOWLEDGMENTS**

This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grants (BB/L007223/1 and BB/P006078/1) to J.B. and the United States Agency...
for International Development (USAID) under the terms of the Saving Lives at Birth Agreement (AID-OAA-F-16-00107) to R.F.D. This work was also supported, in part, by Wellcome Trust grant number UNS39792.

REFERENCES

1. Blencowe H, Vos T, Lee AC, Philips R, Lozano R, Alvarado MR, Cousens S, Lawn JE. 2013. Estimates of neonatal mortalities and disabilities at regional and global levels for 2010: Introduction, methods overview, and relevant findings from the Global Burden of Disease study. Pediatr Res 74:4–16. https://doi.org/10.1038/pr.2013.203.

2. Lee AC, Chandran A, Herbert HK, Kozuki N, Markell P, Shah R, Campbell H, Rudan I, Baqui AH. 2014. Treatment of infections in young infants in low- and middle-income countries: a systematic review and meta-analysis of frontline health worker diagnosis and antibiotic access. PLoS Med 11:e1001741. https://doi.org/10.1371/journal.pmed.1001741.

3. World Health Organization. 2015. Guideline: managing possible serious bacterial infection in young infants when referral is not feasible. World Health Organization, Geneva, Switzerland.

4. Musliime GM, Seale AC, Moxon SG, Lawn JE. 2015. Risk of gentamicin toxicity in neonates treated for possible severe bacterial infection in low- and middle-income countries: systematic review. Trop Med Int Health 20:1593–1606. https://doi.org/10.1111/tmi.12608.

5. Pacifi GM. 2015. Clinical pharmacology of gentamicin in neonates: regimen, toxicity and pharmacokinetics. Med Express 2:1–9.

6. Rao SC, Srinivasjois R, Moon K. 2016. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 12:CD005091. https://doi.org/10.1002/14651858.CD005091.

7. González-Vázquez P, Larrañeta E, McCrudden MTC, Jarrahan C, Rein-Weston A, Quintanar-Solares M, Zehrung D, McCarthy H, Courtenay AJ, Donnelly RF. 2017. Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis. J Control Release 265:30–40. https://doi.org/10.1016/j.jconrel.2017.07.032.

8. Darmstadt GL, Batra M, Zaidi A. 2009. Parenteral antibiotics for the treatment of serious neonatal bacterial infections in developing country settings. Pediatr Infect Dis J 28:S37–S42. https://doi.org/10.1097/INF.0b013e3181958bc3.

9. Hindmarsh KW, Nation RL, Williams GL, John E, French JN. 1983. Pharmacokinetics of gentamicin in very low birth weight preterm infants. Eur J Clin Pharmacol 24:649–653. https://doi.org/10.1007/BF00542216.

10. Obiero CW, Seale AC, Berkeley JA. 2015. Empircic treatment of neonatal sepsis in developing countries. Pediatr Infect Dis J 34:659–661. https://doi.org/10.1097/INF.0000000000000692.

11. Gyawali S, Rathore D, Shankar P, Vikash Kumar K. 2013. Strategies and challenges for safe injection practice in developing countries. J Pharma- col Pharmacother 4:8. https://doi.org/10.4103/0976-500X.107634.

12. Rodgers AM, McCrudden MTC, Vincente-Perez EM, Dubois AV, Ingram RJ, Larrañeta E, Kissenpfennig A, Donnelly RF. 2018. Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: a proof of concept study. Int J Pharm 549:87–95. https://doi.org/10.1016/j.ijpharm.2018.07.049.

13. Rodgers AM, Cordeiro AS, Kissenpfennig A, Donnelly RF. 2018. Microneedle arrays for vaccine delivery: the possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity. Expert Opin Drug Deliv 15:821–867. https://doi.org/10.1080/17425247.2018.1505860.

14. Norman JJ, Arya JM, McClain M, a, Frew PM, Meltzer MI, Prausnitz MR. 2014. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 32:1856–1862. https://doi.org/10.1016/j.vaccine.2014.01.076.

15. Ripolin A, Quinn J, Larrañeta E, Vicente-Perez EM, Barry J, Donnelly RF. 2017. Successful application of large microneedle patches by human volunteers. Int J Pharm 521:92–101. https://doi.org/10.1016/j.ijpharm.2017.02.011.

16. Arya J, Prausnitz MR. 2016. Microneedle patches for vaccination in developing countries. J Control Release 240:135–141. https://doi.org/10.1016/j.jconrel.2015.11.019.

17. McConvilie A, Hegarty C, Davis J. 2018. Mini-review: assessing the potential impact of microneedle technologies on home healthcare appli- cations. Medicines 5:30. https://doi.org/10.3390/medicines5020050.

18. McCrudden MTC, Torrisi BM, Al-Zahrani S, McCrudden CM, Zaric, M, Scott CJ, Kissenpfennig A, McCarthy HO, Donnelly RF. 2015. Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination. J Pharm Pharmacol 67:409–425. https://doi.org/10.1111/jphp.12248.

19. Hayward RS, Harding J, Molloy R, Land L, Longcroft-Neal K, Moore D, Ross J. 2018. Adverse effects of a single dose of gentamicin in adults: a systematic review. Br J Clin Pharmacol 84:223–238. https://doi.org/10.1111/bcp.13439.

20. Vading M, Nauclér P, Kalin M, Giske CG. 2018. Invasive infection caused by Klebsiella pneumoniae is a disease affecting patients with high comorbidity and associated with high long-term mortality. PLoS One 13:e0195258. https://doi.org/10.1371/journal.pone.0195258.

21. Boulos A, Rand K, Johnson JA, Gautier J, Koster M. 2017. Neonatal sepsis in Haiti. J Trop Pediatr 63:70–73. https://doi.org/10.1093/tropej/fmw077.

22. González-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez- López F, Rivero A, Rodríguez-Baño J. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumo- niae. J Antimicrob Chemother 70:905–913. https://doi.org/10.1093/jac/dku043.

23. Shields RK, Clancy CJ, Press EG, Nguyen MH. 2016. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumo- niae. Antimicrob Agents Chemother 60:3187–3192. https://doi.org/10.1128/AAC.02638-15.

24. Rammaert B, Goyet S, Bourg J, Hem S, Te V, Try PL, Mayaud C, Borand R. 2012. Klebsiella pneumoniae related community-acquired acute lower respiratory infections in Cambodia: clinical characteristics and treatment. BMC Infect Dis 12:3. https://doi.org/10.1186/1471-2334-12-3.